Sector News

U.K.-based Almac snags EU site in preparation for Brexit 'uncertainty'

January 19, 2018
Life sciences

While Big Pharma companies have equivocated about whether to pull drug production from the U.K. because of Brexit, CDMO Almac quickly went out and did something about it. It obtained a site in the EU and is now investing about $30 million on upgrades.

Based in Northern Ireland—part of the U.K.—Almac has secured a site 40 minutes away in Dundalk, Ireland, part of the EU. It says EU regulators have recently inspected the site for clinical trial and commercial production.

It now intends to invest £30 million ($41.6 million) to add a quality-control laboratory, commercial drug packaging facility and a 79,000-square-foot EU distribution center for clinical trial supply. It said the expansion will more than triple the manufacturing footprint at the European campus, which it says is slated to be operating by January 2019.

“The announcement today of further expansion will ensure our current and future clients receive a seamless solution with access to the EU marketplace,” Almac CEO Alan Armstrong said in a statement. “Crucially, this will ensure an uninterrupted service provision through any uncertainty Brexit may bring.”

Drugmakers in the EU have been warning of drug supply chaos if the U.K. and European Commission can’t strike a specific deal covering the approval of medicines before their governmental divorce. About 45 million packages of drugs move from the U.K. to the EU each year and 37 million in the other direction, a European Federation of Pharmaceutical Industries and Associations survey found.

GlaxoSmithKline and AstraZeneca, the U.K.’s largest and second-largest drugmakers, have urged the two sides to make sure the pharma issues get resolved ahead of the split but are making contingency plans just in case. AZ’s Pascal Soriot, for example, declared a hiatus on any significant manufacturing investments in the country until there is more light around what the split will mean for pharma.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).